AtriCure, Inc. , a leading innovator in surgical treatments and therapies for atrial fibrillation , left atrial appendage management, and post-operative pain management, today announced that it has.
AtriCure, Inc. (NASDAQ:ATRC) Q4 2023 Earnings Call Transcript February 15, 2024 AtriCure, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.22. AtriCure, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to AtriCure’s Fourth […]